Cardiac Methotrexate-Induced Lymphoproliferative Disorder
Cardiac Methotrexate-Induced Lymphoproliferative Disorder
复制标题
心脏甲氨蝶呤诱发的淋巴细胞增殖性疾病
DOI：
10.1016/j.athoracsur.2019.01.065
复制
发表时间：
2019
期刊：
影响因子：
4.6
通讯作者：
Nakajima H.
中科院分区：
文献类型：
--
作者：
Kaneyuki D;Iguchi A;Tokunaga C;Fukushima K;Sato T;Nakajima H.
据报道，甲氨蝶呤是一种与淋巴组织增生性疾病相关的免疫抑制剂。本报告描述了一个心脏甲氨蝶呤诱导的淋巴组织增生性疾病的情况下，可以区分心脏磁共振成像和氟-18（18F）-氟脱氧葡萄糖正电子发射断层扫描结合计算机断层扫描的主动脉窦瘤破裂。通过组织活检做出明确诊断，该组织活检与主动脉窦动脉瘤修复术同时进行。在甲氨蝶呤停药后观察到显著消退。据我们所知，这是第一例心脏甲氨蝶呤诱导的淋巴组织增生性疾病。
Methotrexate has been reported as an immunosuppressive agent associated with lymphoproliferative disorders. This report describes the case of a cardiac methotrexate-induced lymphoproliferative disorder that could be differentiated from a sinus of Valsalva aneurysm rupture by cardiac magnetic resonance imaging and fluorine-18 (18F)-fluorodeoxyglucose positron emission tomography combined with computed tomography. The definitive diagnosis was made by a tissue biopsy that was concomitantly performed with sinus of Valsalva aneurysm repair. Significant regression was seen in response to methotrexate withdrawal. To the best of our knowledge, this is the first case of a cardiac methotrexate-induced lymphoproliferative disorder.